RAC 2.20% $1.78 race oncology ltd

Ann: Quarterly Activity Report & Appendix 4C, page-11

  1. 63 Posts.
    lightbulb Created with Sketch. 23
    Looks like they aren’t getting distracted by it, too many other opportunities to pursue already that needs to be done comprehensively. Using the paper more as further validation of Zantrene as FTO inhibitor.

    The expected news list is stacking up…
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.